


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-10. (canceled)

11. (previously presented) A compound of general formula (I)



(I)

and pharmaceutically acceptable salts or prodrugs thereof, wherein:

n is 0, 1 or 2;

R¹ and R², independently of each other, are H, OH or OCH₃;

R³ is H or CH₃;

R⁴ is H, C₁-C₃ straight or branched alkyl or, together with R³, forms a five to seven-membered carbocyclic ring;

and R⁵ and R⁶, independently of each other, are H or C₁-C₅ straight or branched alkyl

with the provisos that:

R¹ and R² cannot be both hydrogen;

when n is 0, R¹ and R² are both hydroxyl, R³ and R⁵ are hydrogen, R⁴ cannot be CH₃;

when n is 0, R³ is H and R⁴ is H or CH₃, R⁶ cannot be C₁-C₃ straight or branched alkyl;

and that the compounds cannot be:

- 1-(4-hydroxyphenyl)-2-hydroxylaminoethane,
- 1-(4-hydroxyphenyl)-2-hydroxylaminopropane,
- 1-(4-methoxyphenyl)-2-hydroxylaminopropane,
- 1-(3,4-dimethoxyphenyl)-2-hydroxylaminopropane,
- 1-(4-methoxyphenyl)-4-hydroxylaminobutane
- 1-(3-methoxyphenyl)-2-hydroxylaminopropane,
- 1-(3,4-dimethoxyphenyl)-2-hydroxylaminoethane,
- N-methyl-1-(3,4-dihydroxyphenyl)-2-hydroxylaminopropane,
- 1-(3-methoxy-4-hydroxyphenyl)-2-hydroxylaminopropane,
- N-methyl-1-(3-methoxy-4-hydroxyphenyl)-2-hydroxylaminopropane,
- N-methyl-1-(3,4-dimethoxyphenyl)-2-hydroxylaminopropane.

12. (previously presented) A compound according to claim 11 selected from the group consisting of:

- N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
- N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-hydroxylamine;
- N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-ethyl-hydroxylamine;

- N-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-butyl-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-butyl-O-propyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-ethyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
- N-(1-methyl-2-(3-hydroxy-phenyl)-ethyl)-hydroxylamine;
- N-(1-methyl-2-(3-hydroxy-phenyl)-ethyl)-N-methyl-hydroxylamine;
- N-(1-methyl-2-(3-hydroxy-phenyl)-ethyl)-N-propyl-hydroxylamine;
- N-(1-methyl-2-(3,4-dihydroxy-phenyl)-ethyl)-N-propyl-hydroxylamine;
- N-(1-methyl-2-(3-methoxy-phenyl)-ethyl)-N-methyl-hydroxylamine;
- N-(1-methyl-2-(3-methoxy-phenyl)-ethyl)-N-propyl-hydroxylamine;
- N-(1-methyl-2-(3,4-dimethoxy-phenyl)-ethyl)-hydroxylamine;

- N-(1-methyl-2-(3,4-dimethoxy-phenyl)-ethyl)-N-propyl-hydroxylamine;
- N-(5-hydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5-hydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-O-ethyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-N-methyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-N-propyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-hydroxylamine;

- N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-O-ethyl-hydroxylamine;
 - N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-N-methyl-hydroxylamine;
 - N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-N-propyl-hydroxylamine;
 - N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-N-propyl-O-ethyl-hydroxylamine;
- and the pharmaceutically acceptable salts thereof.

13. (previously presented) Pharmaceutical compositions containing one or more compounds of formula (I) according to claim 11 in a mixture with suitable excipients and/or carriers.

14. (previously presented) Pharmaceutical compositions containing one or more compounds of formula (I) according to claim 11 and a compound for the treatment of central and peripheral nervous system disorders involving protein misfolding and/or misaggregation of beta-amyloid peptide, alpha-synuclein, prion protein and huntingtin selected from Alzheimer's Disease, Lewy body disease, Parkinson's Disease, spongiform encephalopathies, Huntington's Disease and systemic AA amyloidosis, in admixture with suitable excipients and/or carriers.